Skip to content
value.today

cbdMD, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Pharmaceutical: $30 M to $126 M, median $66 MPrice to bookPrice to book of Pharmaceutical: $15 M to $60 M, median $29 M$0 M$34 M$68 M$102 M$136 MMarket value $4 M

Your own DCF model

A full discounted-cash-flow model of cbdMD, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Pharmaceutical

Multiples of its companies with a market value at most 60 days old, times cbdMD, Inc.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)cbdMD, Inc.Applied toValue (25th to 75th)Companies
Price to sales1.5× / 3.5× / 6.6×0.2×revenue $19 M$30 M to $126 M69
Price to book2.1× / 4.0× / 8.3×0.6×book equity $7 M$15 M to $60 M63

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

cbdMD, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.

Price to sales

0.2×

Now below its median of 0.4×, in the bottom quarter of its range; range 0.1× to 3.7× over 20 months.

0×1×2×3×4×2020202120222023202420252026Price to sales 0×Median 0×

Price to book

0.6×

Now below its median of 1.1×, in the bottom quarter of its range; range 0.1× to 6.3× over 30 months.

0×2×3×5×6×2020202120222023202420252026Price to book 1×Median 1×

as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Sep 30, 2025$19 M$-2 M$-1 M$0 M$-2 M—SEC annual report (10-K, 20-F)
FY2024to Sep 30, 2024$19 M$-4 M$-0 M$0 M$-1 M—SEC annual report (10-K, 20-F)
FY2023to Sep 30, 2023$24 M$-23 M$-4 M$0 M$-5 M$-2 MSEC annual report (10-K, 20-F)
FY2022to Sep 30, 2022$35 M$-70 M$-15 M$1 M$-16 M$-7 MSEC annual report (10-K, 20-F)
FY2021to Sep 30, 2021$44 M$-23 M$-14 M$0 M$-14 M$-26 MSEC annual report (10-K, 20-F)
FY2020to Sep 30, 2020$42 M$13 M$-11 M$1 M$-12 M$-15 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value $4 M on Oct 30, 2026.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.